Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS) rectal cancer.

Trial Details

NCT ID
NCT04109755
Phase
PHASE2
Sponsor
University Hospital, Geneva
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Pembrolizumab
Locations (sample)
  • Geneva, Switzerland|46.20222,6.14569

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of rectal …
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the da…
  • Patients with previously untreated localized T3-T4 N0 or T any or N1-2, M0 rectal adenocarcinoma.
  • Tumour must be microsatellite stable (MSS).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →